Thursday August 15, 9:45 am Eastern Time
Press Release
SOURCE: Vernalis Group plc
Frovatriptan Menstrual Migraine Trial Ahead of Schedule
CAMBRIDGE, England, Aug. 15 /PRNewswire-FirstCall/ -- Vernalis Group plc ("Vernalis" LSE: VER) today announced that its clinical trial investigating the use of frovatriptan in the prophylaxis (prevention) of menstrual migraine will be completed ahead of schedule. The Company now expects to report summary findings from the study in early September 2002. ADVERTISEMENT
The trial, a multi-centre, double-blind, placebo-controlled crossover study in over 500 patients suffering from chronic menstrual migraine, was conducted at 34 centres in the United States. Interest in frovatriptan for this potential indication centres around its long half life (26 hours), which is substantially longer than that of other drugs in its class.
Frovatriptan is being marketed in the US by UCB and Elan, targeting neurologists and high prescribing primary care physicians (general practitioners). The Company is delighted by the positive feedback from physicians and patients, and plans to report on frovatriptan's successful US launch at its interim results presentation next month.
This press release contains forward-looking statements, including statements regarding Vernalis' strategy and prospects. Statements that are not historical facts are based on Vernalis' current expectations, beliefs, estimates and assumptions. Such statements are not guarantees of future performance and involve risks, uncertainties and other important factors that may cause Vernalis' actual results, performance or achievements to be materially different from those anticipated by such forward-looking statements. Important factors which may affect Vernalis' future operating results include the following: Vernalis may not receive royalty revenues, milestone payments or other revenues when expected or at all, Vernalis' product candidates may not receive regulatory or marketing approval or gain market acceptance in key markets when anticipated or at all, Vernalis may be unable to conduct its clinical trials as quickly as it has predicted, Vernalis' product candidates may not demonstrate therapeutic efficacy, Vernalis may be unable to obtain sufficient capital when needed to develop its product candidates, and other important factors described in the section entitled "Risk Factors" in Vernalis' Registration Statement on Form 20-F filed with the US Securities and Exchange Commission.
Enquiries:
Vernalis Group plc
Robert Mansfield Chief Executive Officer 0118 977 3133
Peter Worrall Finance Director 0118 977 3133
Noonan Russo Presence Euro RSCG
Donald Murphy 212-845-4274
For previous press releases please see the Vernalis website: vernalis.com
(snip)
Of course, a successful lauch is "eye of beholder" stuff. Vernalis doesn't need "success" on the same scale as does ELN. |
